Boditech Med Inc. [206640.KQ] Stock Forecast

Boditech Med Inc. develops products for in-vitro diagnostics and diagnostic reagents. It offers ichroma II, an automatic or semiautomatic in-vitro diagnostic device that measures the concentration of analytes, contained in blood, urine, or other samples, in quantitative, or semi-quantitative ways; automated fluorescent immunoassay systems under AFIAS-6 and AFIAS-1 names that uses blood, urine, and other samples to measure quantitatively or semi-quantitatively the concentration of targeted analytes; ichroma-50, an automatic immunoassay analyzer that measures the concentration of targeted analytes in body fluids, such as blood, urine, and other samples; and ichroma M2, a portable analyzer intended to be used with in vitro diagnostic immunofluorescent assay kits for screening, monitoring and/or examining routine physics in centralized laboratories of hospitals or physician's clinics. The company also provides Ichroma TRIAS Reader, an in vitro diagnostic device that measures the concentration of targeted analyte from various samples, such as blood, nasal swabs, and nasopharyngeal swabs; Hemochroma PLUS, an in vitro diagnostic device to quantitative test total hemoglobin concentration in the blood; i-chamber, an auxiliary device for the ichroma systems; and HandyRay, a laser device for the capillary blood sampling without a needle. Its solutions cover areas, such as cardiac, cancer, diabetes, hormone, infection, infectious disease, gastrointestinal, rheumatoid arthritis, and others. The company offers its products through a network of approximately 100 sales agencies worldwide. Boditech Med Inc. was founded in 1998 and is headquartered in Chuncheon, South Korea.